Are there any contingency plans or alternative asset programs that Minerva could prioritize if roluperidone faces further regulatory hurdles?

Trading outlook: The FDA’s request for a confirmatory trial on roluperidone (MIN‑101) has already knocked sentiment on Minerva (MNVA) into negative territory (‑20 sentiment) and the stock is likely to trade lower in the near‑term as investors re‑price the regulatory risk. Technically the shares are trading below the 20‑day EMA and have slipped into the lower half of the 50‑day Bollinger Band, with the 200‑day moving average acting as a near‑term support line around $2.20. A break below that level on volume would open the door for a short‑term decline toward the $1.90‑$2.00 zone, while a bounce off the 200‑day average could provide a buying opportunity for risk‑averse traders who believe the company’s pipeline can offset the setback.

Contingency / alternative assets: Minerva’s pipeline beyond roluperidone gives investors a potential “back‑up” story. The company has two other late‑stage programs that could become the primary focus if roluperidone stalls:

1. MIN‑102 (a selective 5‑HT2A inverse agonist) for Parkinson’s‑ disease psychosis – currently in Phase 2/3 with data expected in the next 12‑18 months. A positive readout would provide a near‑term catalyst and a revenue‑generating niche that is less crowded than the schizophrenia market.

2. MIN‑201 (an oral neuro‑protective candidate for Alzheimer’s/major neuro‑cognitive disorder) – early‑stage but backed by a sizable addressable market and a potential partner‑driven financing model.

If the FDA demands a costly confirmatory study, Minerva is likely to re‑allocate R&D capital to accelerate the MIN‑102 trial and seek strategic partnerships for the Alzheimer’s asset. From a trading perspective, watch for any forward‑looking commentary in the next 10‑K or investor webcast that signals a shift of capital to these programs—such hints often trigger short‑term “re‑rating” spikes. In the meantime, a defensive stance (tight stop at $2.00) on the current downside, coupled with a watch‑list for any FDA‑related news (e.g., acceptance of a fast‑track designation for MIN‑102) could allow traders to capture upside if the market begins to price in the “alternative pipeline” narrative.